lar MRD monitoring of ALL patients in Turkey

Müge Sayito¤lu, M Cem Ar, Özden Hat›rnaz, Fieniz Öngören, Ümit Üre, Zafer Bafllar, Sema S›rma, Y›ld›z Ayd›n, U¤ur Özbek, Burhan Ferhano¤lu
2008 Turk J Hematol   unpublished
Objective: Monitoring minimal residual disease has become increasingly important in clinical practice of ALL management. Break-point fusion regions of leukaemia related chromosomal aberrations and rearranged immunoglobulin (Ig) and T cell-receptor (TCR) genes are used as leukaemia specific markers in genetic studies of MRD. Material and Methods: A total of 31 consecutive patients with newly diagnosed ALL were screened for eligibility criteria. Of those 26 were included in the study. One patient
more » ... with partial response following induction therapy and four patients who were lost to follow-up after induction were excluded from the study; thus 21 patients were evaluated for MRD by using polymerase chain reaction (PCR), heteroduplex analysis, sequencing and quantitative real time PCR techniques. Results: Chromosomal aberrations were detected in 5 (24%) of the patients and were used for MRD monitoring. Three patients had t(9;22) translocation, the other 2 had t(4;11) and t(1;19). MRD-based risk stratification of the16 patients analysed for Ig/TCR rearrangements revealed 3 low-risk, 11 intermediate-risk and 2 high-risk patients. Özet Amaç: Minimal rezidüel hastal›¤›n (MRH) takibi, ALL tedavisinin klinik uygulamalar›nda giderek önem kazanmaktad›r. Lösemide s›kl›kla görülen kromozomal k›r›k noktalar› ve immunglobulin (Ig) ve T-hücre reseptörleri (THR), MRH takibinde lösemiye özgü marker olarak kullan›lmaktad›r.
fatcat:byzb2vivfrenvnncctx23vzzli